Magle Chemoswed Holding
3.84 SEK
-4.00 %
Less than 1K followers
MAGLE
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-4.00 %
-50.77 %
-77.80 %
-78.18 %
-80.61 %
-85.12 %
-87.15 %
-90.31 %
-80.89 %
The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. The Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.
Read moreMarket cap
79.29M SEK
Turnover
29.65K SEK
Revenue
282.92M
EBIT %
-44.88 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
10/4
2026
Extraordinary general meeting '26
18/5
2026
Interim report Q1'26
26/5
2026
General meeting '26
All
Press releases
3rd party
ShowingAll content types
Magle Chemoswed Holding AB (publ) initiates written procedure to amend the terms and conditions of its senior secured bonds 2025/2028
Kallelse till extra bolagsstämma i Magle Chemoswed Holding AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools